

Identification of HDAC6 Inhibitor Lead Compounds for the Development of Renal Fibrosis Therapy

Sookmyung Women's University



OTHERS	Lead
Product Type	Small molecules
Indication	Renal fibrosis
Target	HDAC6
MoA(Mechanism of Action)	HDAC6
Competitiveness	- No approved therapeutics directly target and reverse fibrosis. - HDAC6 has emerged as a target with an innovative mechanism, simultaneously regulating multiple fibrotic and inflammatory pathways, including the TGF-β1 signaling pathway central to renal fibrosis. - As no HDAC6-targeted agent has yet entered clinical trials for renal fibrosis, this approach offers an opportunity to develop a first-in-class global therapeutic.
Development Stage	Lead
Route of Administration	PO

Any unauthorized distribution or reproduction of this material is strictly prohibited.